AKBA vs VALU Comparison

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and makes available copyright data, including a ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets its products under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing, and The Most Trusted Name in Investment Research. Its only operating segment is Publishing.